Novartis (NVS)
(Delayed Data from NYSE)
$119.38 USD
+0.88 (0.74%)
Updated Sep 4, 2024 04:00 PM ET
After-Market: $119.37 -0.01 (-0.01%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$119.38 USD
+0.88 (0.74%)
Updated Sep 4, 2024 04:00 PM ET
After-Market: $119.37 -0.01 (-0.01%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth C Momentum C VGM
Zacks News
Here's Why Novartis (NVS) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Top Research Reports for Berkshire Hathaway, Adobe & Alibaba
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc. (BRK.B), Adobe Inc. (ADBE) and Alibaba Group Holding Limited (BABA).
Novartis (NVS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Novartis (NVS) closed at $101.91 in the latest trading session, marking a -1.33% move from the prior day.
Roche's (RHHBY) Evrysdi Gets Label Expansion in EU for Newborns
by Zacks Equity Research
Following the label expansion, Roche's (RHHBY) Evrysdi is now approved to treat people of all ages with SMA in the European Union.
10 Drugs Selected for Medicare Price Reduction
by Zacks Equity Research
10 Drugs Selected for Medicare Price Reduction
Medicare Drugs Targeted Under Inflation Reduction Act
by Mark Vickery
Last year, these 10 drugs made up $50 billion, about 20%, of Medicare part D costs.
The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Merck, Novartis and AstraZeneca
by Zacks Equity Research
Regeneron Pharmaceuticals, Merck, Novartis and AstraZeneca are part of the Zacks top Analyst Blog.
AbbVie (ABBV) Seeks Approval for Skyrizi for Ulcerative Colitis
by Zacks Equity Research
AbbVie's (ABBV) regulatory applications filed to the FDA and the EMA seeking approval for Skyrizi for ulcerative colitis are based on data from two phase III studies.
Novartis (NVS) Announces Positive Long-Term Data on Leqvio
by Zacks Equity Research
Novartis (NVS) Leqvio shows consistent efficacy and safety beyond six years in patients with ASCVD.
Novartis' (NVS) Sandoz Gets FDA Nod for Tysabri's Biosimilar
by Zacks Equity Research
Novartis' (NVS) generic division, Sandoz, wins FDA approval for a biosimilar of the leading MS drug Tysabri.
Oncology Market's Huge Potential Puts These Stocks in Focus
by Sanghamitra Saha
The oncology treatment market has been experiencing significant growth lately. Companies like Regeneron Pharmaceuticals (REGN), Merck & Co. (MRK), Novartis (NVS) and AstraZeneca (AZN) have made meaningful contributions in cancer treatment.
Can AbbVie (ABBV) Protect Revenues After Humira Patent Loss?
by Zacks Equity Research
AbbVie's (ABBV) newer products, Skyrizi and Rinvoq, are performing extremely well and have the potential to make up for lost Humira revenues.
Zacks Industry Outlook Highlights Eli Lilly, J&J, Novo Nordisk, Novartis and AstraZeneca
by Zacks Equity Research
Eli Lilly, J&J, Novo Nordisk, Novartis and AstraZeneca are part of the Zacks Industry Outlook article
5 Large Drug Stocks to Watch as New Drug Approvals & M&A Gain Pace
by Kinjel Shah
Drug, biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), Novo Nordisk (NVO), Novartis (NVS) and AstraZeneca (AZN) are worth retaining in your portfolio.
Novartis (NVS) Plans to Spin-Off Sandoz in Early October
by Zacks Equity Research
Novartis (NVS) progresses with the proposed spin-off of its Sandoz arm (scheduled for early October) and invites shareholders for a meeting on the same.
Pharma Stock Roundup: FDA Okays PFE & JNJ Drugs, EU Approves ABBV's Migraine Drug
by Kinjel Shah
FDA approves Pfizer's (PFE) Elrexfio (elranatamab) for RRMM and J&J's (JNJ) oral combination tablet, Akeega to treat BRCA-positive mCRPC. European Commission approves AbbVie's (ABBV) Aquipta for migraine.
Novartis (NVS) Key Drugs and Pipeline Progress Fuel Growth
by Zacks Equity Research
Novartis (NVS) put up a strong performance year to date based on the solid performance of key drugs and encouraging pipeline progress.
Pharma Stock Roundup: LLY, BAYRY Post Q2 Results, NVO's Wegovy Cuts Heart Attack Risk
by Kinjel Shah
Eli Lilly (LLY), Bayer (BAYRY) and Novo Nordisk (NVO) announce second-quarter results.
Ionis (IONS) Q2 Loss Narrows Y/Y, Sales Surpass Estimates
by Zacks Equity Research
Ionis (IONS) Q2 loss narrows from the year-ago levels. Sales beat estimates. The company re-affirms its previously issued financial guidance for 2023.
Karuna (KRTX) Reports Narrower-Than-Expected Loss in Q2
by Zacks Equity Research
Karuna (KRTX) reports mixed second-quarter 2023 results. The company beats estimates for earnings but misses the mark on sales.
Alnylam (ALNY) Q2 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
Alnylam (ALNY) reports weaker-than-expected second-quarter results. The company also provides updates on its pipeline candidates, which are being developed in collaboration with other pharma bigwigs.
Sarepta (SRPT) Q2 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Sarepta's (SRPT) second-quarter 2023 earnings beat estimates. Though total revenues register strong year-over-year growth during the quarter, the same misses the mark.
Allogene's (ALLO) Q2 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Allogene's (ALLO) second-quarter results beat estimates for earnings but misses the mark on sales. Management reiterated its previously-issued financial guidance for 2023.
United Therapeutics (UTHR) Q2 Earnings & Sales Beat Estimates
by Zacks Equity Research
United Therapeutics' (UTHR) second-quarter 2023 earnings and sales beat estimates. Tyvaso sales continue to drive the company's top line.
Vertex (VRTX) Beats on Q2 Earnings & Sales, Raises '23 View
by Zacks Equity Research
Vertex Pharmaceuticals' (VRTX) second-quarter 2023 earnings and sales beat estimates. Based on strong Trikafta uptake, management raises its financial guidance for 2023.